How Heshmatpour was paid
$0 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Total |
|---|---|---|
| Dr. Thomas C. ChenChief Medical Officer | $212,000 | $212,000 |
| Patrick WaltersChief Operating Officer | — | — |
| Keithly GarnettChief Financial Officer | $179,000 | $179,000 |
| Amir HeshmatpourChief Executive Officer | $0 | $0 |
| Josh NemanChief Clinical Officer | $165,000 | $165,000 |
What changed and why
- $0$0: Amir Heshmatpour's reported 2025 total compensation, including salary, equity, incentives, and other compensation, was unchanged from 2024.
- October 31, 2025: Heshmatpour became CEO after Thomas Chen's CEO service ended.
- 1,200,000 restricted shares: Heshmatpour was promised this grant in connection with becoming CEO.
- $212K$212,000: Chen's 2025 salary remained unchanged, while his title changed to Chief Medical Officer and Chief Scientific Officer.
- $165K$165,000: Josh Neman received this salary after joining as Chief Clinical Officer on June 5, 2025.
- 170,000 restricted shares: David Suh received this grant after becoming Chief Accounting Officer in March 2026.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.